Pretreated PDX Models

Evaluating novel cancer therapies using Champion's biobank of pretreated PDX models offers several benefits, including:

Study Drug Resistance Mechanisms: A robust bank of 700+ pretreated models to investigate how tumors develop resistance to current treatments and identify new targets or strategies to counteract this resistance.

Evaluate Therapeutic Efficacy: Evaluate therapeutic efficacy of your novel therapies by testing them on a bank of pretreated models exposed to the latest therapies such as small molecule inhibitors, chemotherapy, antibodies, immunotherapeutics, and more.

Optimizing your pipeline and discovering new targets: Using pretreated PDX models helps optimize your test agents by understanding molecular interactions between the current line of treatments and cancers and identifying new drug targets, paving the way for more effective second- and third-line therapies.

Reducing Drug Development Costs: Utilizing pretreated PDX models in early drug testing can lower cancer drug development expenses by eliminating ineffective compounds before advancing to costly human clinical trials.

You can access Champions’ database for model selection in Lumin:

Navigate to Lumin.bio and request access to Lumin Analytics.

There, you can use Model Select to search our database filtering for the tumor type and pretreatment of your need. You can also filter for in vivo response, molecular characteristics, and patient profile, to make your model selection the most precise and your studies the most successful. 

Tumors are collected after exposure to prior therapy,  most with multi-line treatment history and matched molecular data.

Yes. Through Lumin, we provide transparent model summaries, filterable by indication, mutation, therapy, and resistance profile.

Absolutely. Our team works alongside your scientists to tailor cohort selection and treatment regimens.

A pretreated PDX model is established from tumor tissue collected after a patient has received one or more lines of therapy. These models reflect resistance phenotypes and molecular adaptations that occur in response to treatment—offering greater translational relevance for drug development.

Our models span a wide range of modern therapies, including:

• Small molecule inhibitors (EGFRi, KRASi, CDK4/6i, PARPi, MEKi, BETi, mTORi, etc.)
• Biologics (trastuzumab, ADCs, bispecific antibodies)
• Immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4)
• Hormonal therapies and chemotherapy
• Experimental agents under clinical investigation

Yes. Many of our models are derived from patients with multiple prior lines of therapy, allowing you to simulate 2nd-line, 3rd-line, or even salvage settings. These models can be especially valuable for combination therapy design, resensitization studies, and late-line response prediction.

Absolutely. We have ADC-exposed cohorts, IO-pretreated models, and immune-resistant tumors. These are ideal for evaluating payload efficacy, tumor penetration, re-sensitization strategies, and biomarker-guided combinations.

Yes. All models come with multi-omic datasets, including mutation/CNV data, RNA expression, and in vivo response. This allows you to correlate biomarkers with therapeutic outcomes and refine patient selection strategies.

Yes. Our models have been successfully used to evaluate radiolabeled compounds, particularly in treatment-resistant settings where standard therapies have failed. We can integrate imaging endpoints, biodistribution, and efficacy into study design.

Use Lumin, our interactive analytics and model selection platform. Filter by tumor type, prior therapy, mutation status, biomarker expression, or resistance profile. If you prefer a collaborative approach, our scientists will work with you to define and recommend a customized cohort.

Yes. Upon request or via Lumin, you’ll receive model summaries including:

• Clinical treatment history
• Tumor histology and site
• Molecular profile
• Prior in vivo response data (where available)

We may have models in expansion or in pre-qualification stages. If needed, we can also discuss custom model development or cohort enrichment strategies. Reach out to our scientific team to explore options.

Most studies using pre-characterized models can start within 10–14 days depending on cohort size, treatment arms, and availability.

Most pretreated models are available in subcutaneous format, but many can be adapted for orthotopic implantation or integrated into humanized systems for specific immune-oncology applications.

Access to models is governed by a standard study agreement or material transfer agreement. We don’t charge additional licensing fees for model use within our CRO services. All studies are conducted within Champions’ facilities under strict quality and ethical guidelines.

Yes. Our scientific team works with you to design protocols that replicate real-world clinical conditions, incorporating relevant prior lines of therapy, biomarker tracking, and combination schedules tailored to your pipeline.